Phase 2 N=29 Intranasal Insulin in Parkinson's Disease
Parkinson Disease
Primary: Safety Measured by Count of Safety Events — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
N/A N=155 Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens
Type 1 Diabetes
Primary: Change in Glycated Hemoglobin- HbA1c — -0.14; -0.09 Change in A1c (%)
Phase 2 N=78 GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy
Primary: Change From the Baseline in the Total Score of PSP-rating Scale — 4.10; 2.14; 6.46 scores on a scale
Phase 3 N=5,047 A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Primary: Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication — 1.3; 1.3; 1.5; 0.8 years
N/A N=62 BCI-FES Therapy for Stroke Rehabilitation
Ischemic Stroke · Hemorrhagic Stroke
Primary: Gait Velocity — 0.38; 0.38; 0.46; 0.45 m/s
N/A N=65 Promotion and Mitigation Factors Leading to Illegal Tobacco Purchases
Cigarette Smoking · Nicotine Vaping
Primary: Percent Budget Spent on Illegal Cigarettes Across Policy Conditions — 40.78; 38.41; 12.14; 9.64 percentage of budget spent
Phase 3 N=504 A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
Postmenopausal Osteoporosis
Primary: To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar…
N/A N=41 An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
Hematologic Malignancies
Primary: Retention Rate — 38; 3 Participants
N/A N=236 Combining Acupuncture and Acupressure for Dementia Elderly
Dementia
Primary: Changes in the Montreal Cognitive Assessment Score — 0.14; 0.70; 1.06; 0.44 score
N/A N=156 Cooling to Alleviate Migraine #3
Migraine With or Without Aura · Migraine · Migraine Headache
Primary: Pain Freedom at 2 Hours Post Treatment — 15; 14 Participants — p=0.7194
Phase 3 N=81 A Study Designed to Evaluate Tear Production
Dry Eye Disease
Primary: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — 519.65 micrometers — p=<0.0001
N/A N=30 Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
Diabetes Mellitus
Primary: Change in Hyperglycemia (Percent Change in HbA1c) — -2.2; -1.0 HbA1c percent change
N/A N=435 A Co-created Self-care and Informal Support Intervention Study Among Women With GDM in Vietnam
GDM
Primary: Large for Gestational Age (LGA) — 23; 17 Participants
Phase 1 N=96 GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Obesity
Primary: Change in Craving Score — -0.7; -0.3 score — p=< 0.001